Release Date: April 29, 2025
Expiration Date: April 29, 2026
Activity Overview
This educational activity is designed to provide expert perspectives on data presented in early 2025 regarding the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). As part of a panel discussion, 2 expert faculty members share their insights on the relevance of these findings on patient management decisions.
Target Audience
This online educational activity is directed toward retina specialists, ophthalmologists, and optometrists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize emerging evidence regarding the treatment of retinal diseases as presented at major medical conferences in 2025
- Recognize patient populations who may benefit from evidence-based therapies used in the management of nAMD based on patient presentation and treatment goals
- Identify appropriate patient populations who may benefit from evidence-based therapies used in the management of DME based on clinical presentation and goals of treatment
- Utilize evidence regarding advanced dosing strategies into individualized treatment for patients with DME
David M. Brown, MD, FACS
Clinical Professor of Ophthalmology
Baylor College of Medicine
Director of Research
Retina Consultants of Texas
Chair, Medical Leadership Board
Retina Consultants of America
Houston, TX
Disclosures: Consulting: AAVantgarde Bio, AbbVie, Alexion, Annexon, Apellis, Bayer, Biogen MA, Boehringer Ingelheim, Celltrion, Chengdu Kanghong, Clearside Biomedical, Heidelberg Engineering, Impact Education, Kowa, Novartis, Ocular Therapeutix, Ocuphire, OPTOS, Pontifax, Regeneron, RetinAI Medical, Ray Therapeutics, Samsung Bioepis, Senju, SIMR Biotech, Stealth BioTherapeutics, THEA, Topcon, Xequel Bio; Grants: AffaMed Therapeutics (US), Alcon, Alexion, Allergan, Amgen, Annexon, Apellis, Astellas, Bayer, BIRC, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside, Eyebiotech, EyePoint, F. Hoffmann-La Roche Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope Therapeutics, Heidelberg Engineering, i-Lumen Scientific, IONIS, Jaeb-/DRCR AA; Jeff Heier, MD; Kodiak Sciences, LumiThera, MeiraGTX, Mylan, NEI/NIH, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocuphire Pharma, OcuTerra Therapeutics, Opthea, OPTOS, Outlook Therapeutics, OXULAR, Oxurion, Pennsylvania State University, Regeneron, Regenxbio, Rezolute, SamChunDang, Samsung, Sandoz, Santen, SciFluor Life Sciences, Senju, Shanghai Henlius Biotech, Stealth BioTherapeutics, Taiwan Liposome Company, Xbrane, Zeiss Meditec; Other: OPTOS (Camera software used to de-warp images); Adverum, Clearside Biomedical, Ocuphire Pharma.
Dilraj S. Grewal, MD
Duke Eye Center
Durham, NC
Disclosures: Consultant: ANI Pharma, Apellis, Astellas, Bausch + Lomb, EyePoint, Regeneron, Roche/Genentech, Zeiss.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here